Compare TRX & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRX | CLLS |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | Canada | France |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 403.8M | 384.3M |
| IPO Year | 2002 | 2014 |
| Metric | TRX | CLLS |
|---|---|---|
| Price | $1.29 | $4.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $1.70 | ★ $8.33 |
| AVG Volume (30 Days) | ★ 3.8M | 27.9K |
| Earning Date | 04-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $84.84 | N/A |
| Revenue Next Year | $96.90 | $0.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $1.33 |
| 52 Week High | $2.80 | $5.48 |
| Indicator | TRX | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 49.45 | 52.20 |
| Support Level | $1.23 | $3.39 |
| Resistance Level | $2.00 | $4.48 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 79.31 | 54.35 |
TRX Gold Corp is engaged in the exploration, development, and production of mineral property interests in the United Republic of Tanzania, focused on development and mining operations, and on exploring and evaluating its mineral properties. The business of exploring and mining for minerals involves a high degree of risk, and the underlying value of the mineral properties depends on the existence and economic recovery of mineral resources and reserves, as well as the ability to raise long-term financing to continue development. The company is focused on the Buckreef Gold Project, which comprises five prospects: Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba, and includes three main mineralized zones: Buckreef South, Buckreef Main, and Buckreef North.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.